AbbVie Inc.

ABBV

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001551152

D

fourth fifth of 367 graded peers in healthcare

rank 232 of 367; percentile 63.1; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	B/C percentile 40.7
Solvency	C/D percentile 59.2
Growth and financing	C/D percentile 58.5
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $134.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	12 of 14
Graded from	filings received through Feb 20, 2026 269 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$295.00 2026-11-13; market equity $521.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 20, 2026

AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.7						
Gross profitability	32.1%	32.3%		47.0	365	2025-12-31
Return on invested capital	17.8%	9.3%		24.7	74	2025-12-31
Accruals ratio	(11.0%)	(6.6%)		38.6	799	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	3.0 pts	2.8 pts	52.7	242	2025-12-31
Solvency, sleeve percentile 59.2					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-09-30					
Altman Z double-prime	not computable	(0.31)			
one or more required annual facts are missing					
Net debt to EBITDA	3.39x	1.82x	71.6	75	2025-12-31
Interest coverage	5.21x	(4.51x)	13.0	78	2025-12-31
Current ratio	0.67x	2.96x	93.0	825	2025-12-31
Growth and financing, sleeve percentile 58.5					
Revenue growth, three-year compound	1.8%	10.1%	67.8	411	2025-12-31
Free cash flow growth, three-year compound	(9.8%)	11.0%	85.1	95	2025-12-31
Reinvestment rate	(6.3%)	37.1%	71.8	104	2025-12-31
Asset growth, three years	(1.2%)	2.3%	54.0	693	2025-12-31
Net share issuance, one year	0.2%	2.4%	13.7	627	2026-02-10

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
227	Amylyx Pharmaceuticals, Inc. (AMLX)	61.7	C/D	degenerate inputs
228	Embecta Corp. (EMBC)	62.0	C/D	late filer
229	Lenz Therapeutics, Inc. (LENZ)	62.3	C/D	short runway
230	Biogen Inc. (BIIB)	62.6	D	
231	Beam Therapeutics Inc. (BEAM)	62.8	D	
232	AbbVie Inc. (ABBV)	63.1	D	
233	Perspective Therapeutics, Inc. (CATX)	63.4	D	dilution, short runway, fortress balance sheet
234	Iovance Biotherapeutics, Inc. (IOVA)	63.7	D	dilution, short runway
235	Royalty Pharma plc (RPRX)	63.9	D	
236	Integra Lifesciences Holdings Corp. (IART)	64.2	D	
237	AIM ImmunoTech Inc. (AIM)	64.5	D	late filer, degenerate inputs, distress

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	22.8%	(1.5%)	63
Distance from 52-week high	0.0%	(32.0%)	97
EBIT to enterprise value	2.6%	(1.8%)	65
Free cash flow yield	3.4%	(1.0%)	72
Book value to price	(0.01)	0.29	10
Sales to price	0.12	0.29	30
Composite equity issuance, five years	(20.6%)	19.1%	8

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	0.04	(0.18)	63

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$10.8B
Operating cash flow, four quarters	$20.1B
Months of runway	not finite
Days since last periodic filing	13 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$1.2B

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$61.2B	2025-12-31	2026-02-20	10-K	26-000008
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$18.2B	2025-12-31	2026-02-20	10-K	26-000008
3	assets	us-gaap:Assets	$134.0B	2025-12-31	2026-02-20	10-K	26-000008
4	operating income	us-gaap:OperatingIncomeLoss	$15.1B	2025-12-31	2026-02-20	10-K	26-000008
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$6.6B	2025-12-31	2026-02-20	10-K	26-000008
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$2.4B	2025-12-31	2026-02-20	10-K	26-000008
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$58.9B	2025-12-31	2026-02-20	10-K	26-000008
8	book equity	us-gaap:StockholdersEquity	-$3.3B	2025-12-31	2026-02-20	10-K	26-000008
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.2B	2025-12-31	2026-02-20	10-K	26-000008
10	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$60.3B	2024-12-31	2026-02-20	10-K	26-000008
11	book equity	us-gaap:StockholdersEquity	$3.3B	2024-12-31	2026-02-20	10-K	26-000008
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$5.5B	2024-12-31	2026-02-20	10-K	26-000008
13	net income	us-gaap:NetIncomeLoss	$4.2B	2025-12-31	2026-02-20	10-K	26-000008
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$19.0B	2025-12-31	2026-02-20	10-K	26-000008
15	assets	us-gaap:Assets	$135.2B	2024-12-31	2026-02-20	10-K	26-000008
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$56.3B	2024-12-31	2026-02-20	10-K	26-000008
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$16.9B	2024-12-31	2026-02-20	10-K	26-000008
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$54.3B	2023-12-31	2026-02-20	10-K	26-000008
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$20.4B	2023-12-31	2026-02-20	10-K	26-000008
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$58.1B	2022-12-31	2025-02-14	10-K	25-000020
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$17.4B	2022-12-31	2025-02-14	10-K	25-000020
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$56.2B	2021-12-31	2024-02-20	10-K	24-000011
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$17.4B	2021-12-31	2024-02-20	10-K	24-000011
24	depreciation amortization	us-gaap:Depreciation	$762.0M	2025-12-31	2026-02-20	10-K	26-000008
25	interest expense	us-gaap:InterestExpense	$2.9B	2025-12-31	2026-02-20	10-K	26-000008
26	current assets	us-gaap:AssetsCurrent	$29.1B	2025-12-31	2026-02-20	10-K	26-000008
27	current liabilities	us-gaap:LiabilitiesCurrent	$43.3B	2025-12-31	2026-02-20	10-K	26-000008
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.2B	2025-12-31	2026-02-20	10-K	26-000008
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$18.8B	2024-12-31	2026-02-20	10-K	26-000008
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$974.0M	2024-12-31	2026-02-20	10-K	26-000008

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$22.8B	2023-12-31	2026-02-20	10-K	26-000008
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$777.0M	2023-12-31	2026-02-20	10-K	26-000008
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$24.9B	2022-12-31	2025-02-14	10-K	25-000020
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$695.0M	2022-12-31	2025-02-14	10-K	25-000020
35	current assets	us-gaap:AssetsCurrent	$25.6B	2024-12-31	2026-02-20	10-K	26-000008
36	current liabilities	us-gaap:LiabilitiesCurrent	$38.7B	2024-12-31	2026-02-20	10-K	26-000008
37	assets	us-gaap:Assets	$134.7B	2023-12-31	2025-02-14	10-K	25-000020
38	assets	us-gaap:Assets	$138.8B	2022-12-31	2024-02-20	10-K	24-000011
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,768,169,012	2026-02-10	2026-02-20	10-K	26-000008
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,765,354,859	2025-01-31	2025-02-14	10-K	25-000020

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.